ArticleFrontiers in pharmacology2023
Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration's adverse event reporting system (FAERS).
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- The molecular mechanism of the adverse effects of the biological and small molecular drugs in the therapy of inflammatory skin diseases - psoriasis and atopic dermatitis.Annals of medicine · 2026Review
- Disseminated Acanthamoeba Infection with Necrotic Skin Lesions and Granulomatous Vasculitis, United States.Emerging infectious diseases · 2026Article
- Inflammatory exacerbation of hepatic alveolar echinococcosis during dupilumab therapy: A case report.IDCases · 2026Article
- Aioli: Standardising Drugs in the FDA Adverse Event Reporting System (FAERS) to RxNorm and Anatomical Therapeutic Chemical (ATC) Codes.Pharmacoepidemiology and drug safety · 2025Article
- Liver-targeted allergen immunotherapy rapidly and safely induces antigen-specific tolerance to treat allergic airway disease in mice.Science translational medicine · 2025Article
- A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database.Scientific reports · 2025Article
- Anti-IL-5 treatment, but not neutrophil interference, attenuates inflammation in a mixed granulocytic asthma mouse model, elicited by air pollution.Respiratory research · 2025Article
- Inhibition of EETosis with an anti-citrullinated histone antibody: a novel therapeutic approach for eosinophilic inflammatory disorders.Frontiers in immunology · 2025Article
- Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness.Frontiers in pharmacology · 2025Review
- The role of immunoglobulin E in non-atopic disorders.Frontiers in immunology · 2025Review
- Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities.Journal of leukocyte biology · 2024Review
- Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System.Therapeutic advances in drug safety · 2024Article
- European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned.Frontiers in allergy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.